Welcome to our dedicated page for Context Therapeutics SEC filings (Ticker: CNTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Context Therapeutics Inc. filings document a Nasdaq-listed clinical-stage biopharmaceutical company developing T cell engaging bispecific antibodies for solid tumors. Form 8-K reports include Regulation FD corporate presentations, operating and financial results, clinical-trial updates, and the FDA Fast Track designation for CTIM-76 in platinum-resistant ovarian cancer.
Proxy and governance filings describe annual meeting matters, director elections, stockholder voting procedures and common stock matters. Charter-related material-event reports document corrections to certificate provisions governing director terms and removal rights, along with associated Delaware court and stockholder-governance disclosures.
Context Therapeutics (CNTX) launched an at‑the‑market offering of up to $75,000,000 of common stock under an amended Sales Agreement with Leerink Partners. Shares may be sold from time to time on Nasdaq or other markets as defined in Rule 415(a)(4), with Leerink acting as sales agent on commercially reasonable efforts terms.
The company will receive the proceeds from any sales and expects to use them for research and development, working capital and general corporate purposes, which may include acquiring additional assets. Leerink Partners will earn up to 3.0% of aggregate gross proceeds as compensation. From December 2024 through October 2025, the company previously sold 14,705,882 shares under the program for $15.0 million gross and $14.5 million net.
CNTX’s common stock trades on Nasdaq under “CNTX”; the last reported price was $1.21 per share on October 22, 2025. The filing highlights potential dilution and pricing variability typical of ATM programs.
Context Therapeutics reported that it has regained compliance with Nasdaq’s Minimum Bid Price Rule. Nasdaq notified the company on October 17, 2025 that the closing bid price of CNTX common stock has been at $1.00 per share or greater for the last 10 consecutive business days, and that the matter is closed.
The company previously received deficiency notices and an extension to regain compliance until February 23, 2026. This update confirms CNTX remains listed on Nasdaq under the rule.
Context Therapeutics Inc. reported that Nasdaq has granted the company an additional 180 days, until February 23, 2026, to regain compliance with Nasdaq’s minimum bid price requirement of $1.00 per share under Listing Rule 5550(a)(2). This follows an earlier notice received on February 27, 2025, that the company’s stock had traded below the $1.00 minimum closing bid price for 30 consecutive business days.
The new extension does not immediately affect the listing or trading of the company’s common stock on Nasdaq. Context Therapeutics plans to monitor its share price and is evaluating options to regain compliance, including a potential reverse stock split, but it notes there is no assurance it will meet the requirement by the extended deadline.
Context Therapeutics Inc. Schedule 13G/A discloses that Great Point Partners, LLC and two principals, Dr. Jeffrey R. Jay and Ms. Lillian Nordahl, report shared beneficial ownership of 4,683,711 shares of Context Therapeutics common stock, representing 5.22% of the outstanding class based on 89,704,194 shares outstanding. The filing states Great Point is investment manager to two record holders (BVF and BOVF) whose holdings are included in the aggregate, while the reporting parties disclaim beneficial ownership except to the extent of pecuniary interests. The report is filed jointly under a dated joint filing agreement and affirms the holdings were not acquired to influence control.
Avidity Partners and affiliated funds filed a Schedule 13G reporting significant passive holdings in Context Therapeutics Inc. The filing discloses that certain Avidity reporting persons hold shared voting and shared dispositive power over 9,126,176 shares, representing approximately 9.9% of the outstanding common stock. Individual fund positions reported in the filing include Avidity Master Fund LP with 5,183,700 shares (5.6%) and Avidity Private Master Fund I LP with 7,776,296 shares (8.4%). Michael Gregory is listed among the reporting persons with the same shared power totaling 9,126,176 shares.
The filing indicates no sole voting or dispositive power for any reporting person and includes a certification that the securities were not acquired to change or influence control of the issuer. Exhibits referenced in the filing include a Joint Filing Agreement and Control Person Identification.